Gene therapy digest – 2021 Gene therapy digest – 2021 2 year hold on Zolgensma’s intrathecal OAV-101 lifted (NOVARTIS) OAV-101 (SMN1 replacement gene therapy; Phase 3) – Novartis OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients may […]